Assessing the repurposing potential of disease-modifying antirheumatic drug targets to reduce Alzheimer's disease risk: a pQTL-based Mendelian randomization and colocalization analysis
Mendelian randomization analysis explored DMARD targets and their role in reducing Alzheimer's disease risk, suggesting implications for future therapies.
Key Points
The study investigates the connection between DMARD targets and Alzheimer's disease risk.
Mendelian randomization analysis revealed a 10% increase in AD risk associated with FCGR3B protein levels.
Only one DMARD target, FCGR3B, showed potential risk association, while others did not.
The findings highlight the need for further research on targeting FCGR3B to mitigate AD risk.